Ftse Mib
36.429,72
0,16%
DAX
21.727,20
0,48%
S&P 500
6.071,17
0,53%
NASDAQ
19.681,75
0,25%
Bitcoin
104.299,99
-0,42%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PainReform Ltd (PRFX) PainReform Ltd (PRFX) Notizie

PRFX

PainReform (PRFX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRFX
DataOraFonteTitoloSimboloCompagnia
02/01/202522:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
02/01/202522:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
27/12/202414:30GlobeNewswire Inc.PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110NASDAQ:PRFXPainReform Ltd
13/12/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
12/12/202423:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PRFXPainReform Ltd
06/12/202422:30Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
20/11/202414:30GlobeNewswire Inc.PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNASDAQ:PRFXPainReform Ltd
07/11/202423:00GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNASDAQ:PRFXPainReform Ltd
11/09/202414:30GlobeNewswire Inc.PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
10/09/202415:46GlobeNewswire Inc.PainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsNASDAQ:PRFXPainReform Ltd
28/08/202422:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:PRFXPainReform Ltd
27/08/202423:07Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRFXPainReform Ltd
21/08/202414:30GlobeNewswire Inc.PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresNASDAQ:PRFXPainReform Ltd
20/08/202414:30GlobeNewswire Inc.PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyNASDAQ:PRFXPainReform Ltd
15/08/202414:00GlobeNewswire Inc.PainReform Provides Business Update for the Second Quarter of 2024NASDAQ:PRFXPainReform Ltd
12/08/202415:00GlobeNewswire Inc.PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsNASDAQ:PRFXPainReform Ltd
07/08/202416:00GlobeNewswire Inc.PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesNASDAQ:PRFXPainReform Ltd
05/08/202415:00GlobeNewswire Inc.PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
01/08/202414:30GlobeNewswire Inc.PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureNASDAQ:PRFXPainReform Ltd
24/07/202414:30GlobeNewswire Inc.PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingNASDAQ:PRFXPainReform Ltd
26/06/202414:00GlobeNewswire Inc.PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110NASDAQ:PRFXPainReform Ltd
31/05/202422:15GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:PRFXPainReform Ltd
15/05/202422:05GlobeNewswire Inc.PainReform Provides Business Update for the First Quarter of 2024NASDAQ:PRFXPainReform Ltd
08/05/202414:30GlobeNewswire Inc.PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comNASDAQ:PRFXPainReform Ltd
18/04/202420:19GlobeNewswire Inc.PainReform Announces Closing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
16/04/202414:00GlobeNewswire Inc.PainReform Announces Pricing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
09/04/202415:00GlobeNewswire Inc.PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsNASDAQ:PRFXPainReform Ltd
02/04/202414:30GlobeNewswire Inc.PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyNASDAQ:PRFXPainReform Ltd
01/03/202422:34Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PRFXPainReform Ltd
01/03/202414:00GlobeNewswire Inc.PainReform Provides Year-End Business UpdateNASDAQ:PRFXPainReform Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRFX

La tua Cronologia

BIT
STMMI
ST Microelectronics
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENAV
Enav
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
G
Generali
BIT
CPR
Davide Campari
BIT
TIT
Telecom Italia
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci